Starling Oncology
STLN
21 hedge funds and large institutions have $50.8M invested in Starling Oncology in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
21.97% more ownership
Funds ownership: 0% → 21.97% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS O'Connor
Chicago,
Illinois
|
+$13.7M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.93M |
| 3 |
HBK Investments
Dallas,
Texas
|
+$4.97M |
| 4 |
Fir Tree Capital Management
New York
|
+$2.49M |
| 5 |
Moore Capital Management
New York
|
+$2.49M |
Top Sellers
STLN Hedge Fund Activity: Q2 2020 in Review
21 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q2 2020, worth a combined $50.8M.
Buyers outnumbered sellers: 21 funds opened new STLN positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $13.7M.
- 21 institutional investors held Starling Oncology (STLN) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $50.8M of Starling Oncology stock for Q2 2020.
- 21 funds opened new Starling Oncology positions in Q2 2020 and 0 closed out, a net change of +21 holders.
- The largest Starling Oncology buyer in Q2 2020 was UBS O'Connor, an estimated $13.7M added.
Based on aggregated 13F filings for Q2 2020.